Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation

Author： Ong Frank S   Deignan Joshua L   Kuo Jane Z   Bernstein Kenneth E   Rotter Jerome I   Grody Wayne W   Das Kingshuk  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.13, Iss.4, 2012-03, pp. : 465-475

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Implementation of Cardiovascular Disease Prevention Guidelines into Clinical Practice: an Unmet Challenge?

By  

Current Pharmaceutical Design, Vol. 21, Iss. 9, 2015-03 ,pp. : 1180-1184

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Utility of Biomarkers in Premature Atherosclerosis

By  

Current Medicinal Chemistry, Vol. 19, Iss. 16, 2012-06 ,pp. : 2521-2533

Bentham Science Publishers

Access to resources Recommend Favorite

Tumor Biomarkers: Clinical Utility, Promises and Problems

By  

Applied Clinical Research, Clinical Trials and Regulatory Affairs, Vol. 1, Iss. 1, 2014-04 ,pp. : 51-55

Bentham Science Publishers

Access to resources Recommend Favorite

Novel Inflammatory Biomarkers in Cardiovascular Therapeutics

By  

Current Medicinal Chemistry, Vol. 22, Iss. 23, 2015-01 ,pp. : 2773-2785

Bentham Science Publishers

Access to resources Recommend Favorite

An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice

By Leeming D.   Alexandersen P.   Karsdal M.   Qvist P.   Schaller S.   Tankó L.  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 10, 2006-10 ,pp. : 781-792

Springer Publishing Company

Access to resources Recommend Favorite